Report
Martial Descoutures ...
  • Sebastien Malafosse

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...
Underlying
UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Sebastien Malafosse

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch